“Two new studies use new models to identify genetic targets and test promising treatments for adrenal cancer. One patient was treated with the immunotherapy pembrolizumab and now more than a year afterRead More…
There is no doubt that this year marks the beginning of CAR-T therapy owing to the advent of two CAR-T therapies and the changes that these therapies have brought to the lives ofRead More…
Actemra/RoActemra® is the first FDA approved drug for treatment of serious or fatal cytokine release syndrome (CRS) caused by CAR-T therapy; CAR-T cell therapy is an immunotherapy used to treat certain typesRead More…
On August 24th, a reporter was informed from Prof. Guangmei Yan research group at Zhongshan University that this group of researchers identified and gained oncolytic virus M1 synergist with accurate treatment ofRead More…
Car-T for Autoimmune Disease An autoimmune disease is a pathological condition resulting from an abnormal immune response to tissues that can exist in the body, affecting up to 50 million Americans in termsRead More…
Chimeric antigen receptor (CAR) modified T cells (CAR-T) as a new field of adoptive immune cell therapy has become a hot spot in recent research. In 1989, Israeli scholar Gross et al.Read More…
Chimeric antigen receptor (CAR) T cells have hit the cancer immunotherapy area in the past few years. ‘A CAR therapy for cancer, using a technique called adoptive cell transfer, has been approvedRead More…
In this month, FDA oncologic Drugs Advisory Committee agreed to the approval of Novartis’s CAR-T CTL019 therapy on a vote of 10:0 for the treatment of relapsed or refractory children and youngRead More…
Biological therapy includes a variety of models, such as immunotherapy, gene therapy, regulation of angiogenesis therapy, small molecule targeting drugs and stem cells and tissue engineering regenerative medicine. Among them, cancer immunotherapyRead More…
CAR-T is chimeric antigen receptor T cell immunotherapy, which modifies T cell receptor by CAR and transforms it into the scFV segment in the binding domain of monoclonal antibodies. A classic CAR-TRead More…